Overview

In this interactive case-based lecture, the faculty will answer the question “what is kidney disease?” and identify the common tests used to diagnose this often-silent disease. Additional slides will be devoted to interpreting urinalysis. The faculty will discuss diabetic kidney disease (DKD), the leading cause of chronic kidney disease (CKD), and how to manage it. The management portion of this lecture will emphasize the importance of renin-angiotensin aldosterone system (RAAS) inhibition and hypoglycemic agents in slowing the progression of CKD. You will receive an overview of common medications that require additional monitoring and learn more about renal replacement therapy in patients with comorbid diseases.

Please note that any data, indications, and guidelines presented in this activity are current as of the recording/release on February 7, 2020 and they are subject to change as new information is published. 

Learning Objectives

  • Diagnose kidney disease with cost-effective and appropriate testing
  • Recognize the national burden of diabetic kidney disease (DKD) and identify strategies to treat patients with DKD
  • Describe the principles of safe medication prescribing for patients with chronic kidney disease (CKD)
  • Apply shared-decision making principles to treat patients with advanced CKD and co-morbid disease

     

     

     

Faculty

Rajeev Raghavan, MD

Associate Professor, Department of Medicine Selzman Institute for Kidney Health
Baylor College of Medicine
Houston, TX 

Disclosures

The following relevant financial relationships have been disclosed by faculty: 

Rajeev Raghavan, MD 

No financial relationships disclosed.  

Non-faculty contributors involved in the planning, development, editing, and review of the content have disclosed no relevant financial relationships. 


CME/CE Information

AMA PRA Category 1 Credits

Accreditation Statement

pmiCME is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.


Designation Statement

pmiCME designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For APRNs and PAs, AANPCB and NCCPA accept AMA PRA Category 1 Credit™ as the number of hours of participation (AANPCB) or as Category 1 CME credits (NCCPA).

Commercial Supporter

Not Applicable

Education Partner

Not Applicable


Fine Print

Internet Explorer (version 9.0 and above) is the minimum supported browser for Pri-Med Online eCME activities. Your Internet settings should be set to accept cookies and JavaScript. If cookies and/or JavaScript are disabled, the site may not function properly. A high-speed Internet connection (DSL, cable modem, or LAN-based) is not required; however, it is recommended for faster download times.

The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed by, nor do they necessarily reflect, those of their affiliated institutions, Pri-Med Institute, Pri-Med Institute Advisory Boards and Consultants, DBC Pri-Med, LLC.

Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients.

Pri-Med Institute educational activities are developed and conducted in accordance with the ACCME's Essential Areas and Policies. It is the mission of Pri-Med Institute to develop and present educational activities that are timely, fair-balanced, scientifically rigorous, and that serve to improve patient outcomes. To that end, we welcome your comments about how to better serve your needs.

Pri-Med Institute Accredited Provider
Pri-Med programs are owned and operated by DBC Pri-Med, LLC, a division of Diversified Communications, Inc. Pri-Med Institute, the accredited division of Pri-Med, is accredited with commendation by the ACCME and approved as a provider of continuing education by the AANP. Pri-Med Institute is the accredited provider for this activity.

Disclosures and Conflict of Interest
Pri-Med Institute requires all individuals in a position to influence educational content for Pri-Med Institute-certified CME/CE activities to disclose relevant personal financial relationships with commercial interests prior to contributing to its educational activities. Pri-Med Institute assesses disclosed relationships and follows a defined process to resolve real or implied conflicts to ensure, to the best of its ability, that all educational content is free of commercial bias. Financial disclosures are listed in the activity syllabus and will also be printed on the slides and announced at the start of each presentation.

Discussion of Off-Label Uses and Investigational Products
During the course of their presentations, the faculty may mention uses of products that have not been approved in the United States for the indication(s) being discussed. All presenters are instructed to notify participants when they are discussing unapproved uses or investigational agents. In addition, specific slides will include notation of the off-label use or investigational agent being discussed. Views presented related to unapproved uses of products are solely those of the presenter(s) and are not endorsed by Pri-Med Institute or DBC Pri-Med, LLC.

Questions? If you have questions about this activity, please email support@pri-med.com or call (877) 477-4633.